HOME >> BIOLOGY >> NEWS
Awards honor Alt's three decades of genetic cancer research

Frederick W. Alt, a Howard Hughes Medical Institute investigator at the Children's Hospital Boston Department of Molecular Medicine, has received the Clowes Memorial Award from the American Association for Cancer Research, acknowledging his three decades of seminal discoveries in genomic instability and cancer. The Clowes is the oldest award given by the AACR, and recognizes outstanding recent accomplishments in basic cancer research. The award will be presented at the AACR's 95th Annual Meeting in Orlando, Fla. (March 27-31, 2004). This month Alt, who holds a doctorate in Biological Sciences, also received the prestigious Scientific Leadership Award in Immunology from the Irvington Institute for Immunological Research in New York City.

Alt was the first to elucidate a molecular mechanism for genomic instability (an increased tendency to develop gene mutations) involved in promoting cancer. The human genome is at constant risk for mutations due to environmental insults, errors in gene replication, and other factors that can cause chromosomes to break and bits of DNA to be lost, duplicated, or reshuffled to the wrong chromosomes (translocated). Cells have repair mechanisms that constantly fix this damage, but when the repair process breaks down, the genome becomes unstable and cancers are more likely to develop.

Alt's wide-ranging research has important implications for cancer prevention and has sparked much additional research by other scientists. His work has touched on many aspects of genomic instability and cancer. Several key advancements specifically cited by the AACR are detailed below, followed by a description of Alt's more recent work.

Gene amplification

Alt's early work, as a student with Robert Schimke in the 1970s, led to the discovery of a major form of genomic instability known as gene amplification, or creation of many duplicate copies of a gene, sometimes even numbering in the thousands. Studying how
'"/>

Contact: Susan Craig
susan.craig@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
24-Mar-2004


Page: 1 2 3 4 5

Related biology news :

1. Institute for OneWorld Health nominated for the 2004 World Technology Awards
2. Presidential Recognition Awards presented at the 2004 AIUM Annual Convention
3. Workforce achievements celebrated at NASA Marshall Center Awards ceremony
4. APS announces 2004 Distinguished Lecturer Awards
5. Last call for nominations for 2004 National Academies Communication Awards
6. Mind Science Foundation announces Rare Consciousness Research Awards
7. The DFG announces EURYI Awards for Germany
8. Three Pacific Northwest National Laboratory inventions win R&D 100 Awards
9. Call for entries: Science Journalism Awards
10. Heinz Maier-Leibnitz Awards 2003
11. Six reporters named to receive 2002 AAAS Science Journalism Awards

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2019)... ... May 20, 2019 , ... The ASGCT Clinical Trials Finder is ... throughout the United States. Data curated daily from ClinicalTrials.gov ensures the most up-to-date and ... who volunteered to assist in the development of the ASGCT Clinical Trials Finder ...
(Date:5/15/2019)... , ... May 15, 2019 , ... ... process of histology wherein tissues are cut into ultra-thin two-dimensional slices, placed on ... in the context of the brain is that the brain is a highly ...
(Date:5/8/2019)... Texas (PRWEB) , ... May ... ... Gary Hutchinson has been accepted into Forbes Technology Council, an invitation-only community ... Inc. Verified Company, is a full-service biopharmaceutical cold chain engineering firm that ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... Calif. (PRWEB) , ... April 09, 2019 , ... ... services firm focused on increasing the capacity of life sciences organizations to accelerate ... Cloud Assurance platform in the past 12 months. , USDM’s ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific ... CARB-X has proceeded with a second stage of funding for Specific’s Reveal™ rapid ... is on top of the $1.7 million already awarded by CARB-X. The additional ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... collection, and analysis to a team of researchers at Nnamdi Azikiwe University in ... Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences and ...
Breaking Biology Technology:
Cached News: